Please login to the form below

Not currently logged in
Email:
Password:

ACNielsen HCI joins Kantar

ACNielsen HCI, a promotion research organisation focused on healthcare, has joined Kantar Health's Marketing Insights practice

ACNielsen HCI, a promotion research organisation focused on healthcare, has joined Kantar Healths Marketing Insights practice.

Since its inception in 1982, HCI has studied nearly 8,000 pharmaceutical campaigns to develop a systematic process to improve a campaign's development and promotion from pre-launch promotional budget planning to measuring sales performance. HCI's Professional Health Communication Measurement services deliver actionable research about the media usage tactics that impact the healthcare market. 

HCI's campaign tracking solutions will augment Kantar Health's portfolio of complementary solutions for pharmaceutical marketers. In addition, their combined physician panels will provide clients with greater research coverage across physician specialities.

"I'm confident this change will offer exciting new growth opportunities for Kantar Health's business," said Les Leathem, senior vice president, Kantar Health. "I'm also confident that Kantar Health is receiving a terrific new capability and a highly talented and seasoned team of healthcare research professionals."

8th February 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics